Molekular zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms
B. M. Fischer , W. Eberhardt , R. Buhl , R. Pirker
Onkologe 12 ( 8) 769 -779
2006
PC05.03 ICIs for Patients with Immune-Related Comorbidity
R. Pirker
Journal of Thoracic Oncology 14 ( 10)
2019
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
M-S Tsao , G Le Teuff , FA Shepherd , C Landais
Annals of Oncology 28 ( 4) 882 -889
111
2017
Randomized phase III trial of Taxol®/Carboplatin versus Taxol®Cisplatin in patients with advanced non-small cell lung cancer
R. Rosell , U. Gatzemeier , D. Betticher , U. Keppler
Lung Cancer 25
1999
114 Vinorelbine/gemcitabine in advanced non-small-cell lung cancer (NSCLC): A phase I trial
R. Pirker , G. Krajnik , W. Wein , A. Mohn-Staudner
Lung Cancer 18 32
2
1997
200 Gemcitabine in the treatment of advanced non-small-cell lung cancer: A phase II trial
R. Malayeri , E. Ulsperger , G. Baumgartner , B. Forstner
Lung Cancer 18 52 -53
1
1997
[Molecular genetic tests in advanced non-small cell lung cancer: practical relevance].
M. Sebastian , N. Niederle , M. Thomas , M. Reck
Deutsche Medizinische Wochenschrift 139 ( 41) 2096 -2100
8
2014
Strategien zur Überwindung der erworbenen EGFR-TKI-Resistenz durch T790M spezifische Substanzen am Beispiel von Osimertinib
F. Griesinger , S. Radke , A. Lüers , B. Deschler-Baier
Pneumologie 72 ( 11) 774 -781
1
2018
VMCP Chemotherapy With or Without Interferon-alpha-2 in Newly Diagnosed Patients With Multiple Myeloma
P. Preis , W. Scheithauer , E. Fritz , C. Zielinski
Onkologie 12 ( 1) 27 -29
5
1989
Conquering lung cancer: current status and prospects for the future.
R. Pirker
Pulmonology 26 ( 5) 283 -290
10
2020
3109 nab-Paclitaxel (nab-P) plus carboplatin (C) as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC): Clinical outcomes by treatment cycle
C. Gridelli , L. Li , M. O'Brien , T.J. Ong
European Journal of Cancer 51
2015
Relationship Between EGFR Expression Level, EGFR Mutation Status and the Efficacy of Chemotherapy Plus Cetuximab in Flex Study Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
J. Douillard , R. Pirker , K.J. O'Byrne , K.M. Kerr
Annals of Oncology 23
2012
Prognostic and Predictive Biomarkers for Act (Adjuvant Chemotherapy) in Resected Non-Small Cell Lung Cancer (R-Nsclc): Lace-Bio
LK Seymour , G Le Teuff , M Tsao , E Brambilla
Annals of Oncology 25 iv58
2
2014
Effectiveness of Darbepoetin Alfa (Da) for Chemotherapy-Induced Anaemia (Cia) When Initiated at Haemoglobin (Hb) ≤10 G/Dl
R. Pirker , J.F. Vansteenkiste , M. Hedenus , E. Hernandez
Annals of Oncology 25 iv524
2014
MULTIDRUG RESISTANCE IN LEUKEMIAS AND ITS REVERSAL
R Malayeri , M Filipits , RW Suchomel , S Zöchbauer
Leukemia & Lymphoma 23 451 -458
31
1996
Application and safety of erythropoietin in cancer management.
R. Pirker , W. Minar
Annals of Oncology 16
3
2005
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial
R. Rosell , U. Gatzemeier , D.C. Betticher , U. Keppler
Annals of Oncology 13 ( 10) 1539 -1549
260
2002
Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer
G. Goeckenjan , H. Sitter , M. Thomas , D. Branscheid
Pneumologie 64 ( 01) 39 -59
210
2011
The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer.
Daniela Kandioler-Eckersberger , S. Kappel , M. Mittlböck , G. Dekan
The Journal of Thoracic and Cardiovascular Surgery 117 ( 4) 744 -750
54
1999
Rate of hemoglobin (Hb) decline from less than 10 g/dl to less than 9 g/dl in placebo-treated patients (pts) receiving chemotherapy: A pooled analysis of data from six randomized darbepoetin alfa trials.
R. Pirker , H. Collins , J. C. Legg , J. F. Vansteenkiste
Journal of Clinical Oncology 29
2
2011